Compare FG & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FG | BLLN |
|---|---|---|
| Founded | 1959 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.4B |
| IPO Year | 2023 | 2025 |
| Metric | FG | BLLN |
|---|---|---|
| Price | $23.19 | $104.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $31.00 | ★ $126.71 |
| AVG Volume (30 Days) | 470.7K | ★ 501.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | ★ 1.24 | 0.48 |
| Revenue | ★ $5,731,000,000.00 | $305,112,000.00 |
| Revenue This Year | $7.94 | $46.29 |
| Revenue Next Year | $5.51 | $30.14 |
| P/E Ratio | ★ $18.66 | $220.69 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $20.57 | $61.96 |
| 52 Week High | $35.33 | $150.44 |
| Indicator | FG | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 52.70 |
| Support Level | $22.18 | $79.07 |
| Resistance Level | $25.36 | $108.50 |
| Average True Range (ATR) | 0.70 | 5.08 |
| MACD | 0.12 | 1.83 |
| Stochastic Oscillator | 21.80 | 61.93 |
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.